Search

Your search keyword '"Ross Warren"' showing total 353 results

Search Constraints

Start Over You searched for: Author "Ross Warren" Remove constraint Author: "Ross Warren"
353 results on '"Ross Warren"'

Search Results

1. Controlling energy levels and Fermi level en route to fully tailored energetics in organic semiconductors

3. A Generalizable Deep Learning System for Cardiac MRI

4. A Generalizable Deep Learning System for Cardiac MRI.

6. Adduct-based p-doping of organic semiconductors

7. Understanding the Double Doping of Organic Semiconductors Via State Energy Renormalization upon Charging

8. Molecular p-doping induced dielectric constant increase of polythiophene films determined by impedance spectroscopy

11. Doping Approaches for Organic Semiconductors

14. Energy levels in organic semiconductors: tuning and doping

15. Efficiency enhancement of small molecule organic solar cells using hexapropyltruxene as an interface layer

16. Characterization of Hydrothermal Deposition of Copper Oxide Nanoleaves on Never-Dried Bacterial Cellulose

17. The end of CME as we know it: Pfizer's recent decision to pull the plug on direct funding of CME through independent commercial providers follows months of public criticism of pharma support. Lew Miller and Warren Ross explore how the rest of the industry is coping with the assault

18. Chasing the pot of gold: the pioneers of biotech began their journey with an endless level of optimism and promise. So, why has the goal of redefining the landscape and achieving the blockbuster success the likes of Big Pharma proven so elusive?

19. What's up with the FDA? What, if anything, is wrong with FDA? And who's to blame: the agency's leadership or its massed ranks of critics? These are just some of the questions Warren Ross posed to an opinionated panel of agency alumni and observers in the know

20. Conscientious objectives: while big pharma scrambles to meet the demands of shareholders, Warren Ross looks at how two nonprofit drug firms--PolyTherics and OneWorld Health--are attempting to upset the patent cart

21. Are NDA Laws constitutional? It will be an interesting month for the drug approval process, with Federal Circuit Court, FDA and Congress all considering whether terminally ill patients should have wider access to unapproved drugs. Warren Ross finds out what's at stake for the industry

22. The side effects of side effects: the recent Institute of Medicine report pointed its institutional finger at the FDA over a variety of shortcomings surrounding drug safety post-marketing surveillance. Warren Ross reports on the potential ramifications for the pharmaceutical industry

23. The battle of New Hampshire: a state law banning commercial use of prescription audit data is meant to protect physicians' privacy. But its effects on industry could be potentially damaging

24. Head to head: head-to head trials are becoming the gold standard in clinical testing. But while a good contest can win a brand formulary freedom and promotional bragging, marketers might find themselves up against more than their rival's efficacy. Warren Ross is ring-side

25. FDA at 100: alumni take its temperature: as the Food and Drug Administration prepares to celebrate its centenary, six former senior FDA-ers talk to Warren Ross about the agency's mission going forward, its leadership, drug safety, Plan B and the Critical Path initiative

27. Women of the C-suite: when it comes to the advancement of women, the pharmaceutical industry has rarely had a reputation as a shining beacon of equal opportunity. But times are changing, and there are signs that more and more women are reaching the top. Warren Ross talks to five such women about how they made it in pharma, and what advice they would offer to others

28. Out of the lab and into the courts

29. Revival of the beta blocker

30. 'We won't bite': Mark McClellan and Peter Pitts, the top officials of the Food and Drug Administration, would like the adversarial relationship with the pharma industry to end. But just how friendly can regulators be?

31. Ritalin's revival: the Novartis marketing team handling the launch of Ritalin LA last year had to overcome a raft of issues that threatened the product's potential. Editor-at-large Warren R. Ross reports on the strategy the team devised

32. New rules, new roles for the sales force: Warren Ross talks with a panel of experts about how the new PhRMA marketing code is upsetting the sales force apple cart

33. Medical advertising isn't what it used to be...: but is it better or worse?

35. How to thrive in a tough environment: top agency CEOs discuss growth strategies in a time of volatility. (An MM&M Executive Roundtable)

36. Get ready for the 'perfect storm': a panel of industry insiders looks at what's ahead

38. M.D. Internet protals open gateways to marketing opportunities. (M.D. Internet Portals)

39. Marketing in 2001: Why Won't the Cheese Stand Still? (MM & M Executive Roundtable)

42. Anthrax vaccine is too risky

43. Why Rubin-Ehrenthal sticks exclusively to DTC accounts

44. Butting in or helping out?; the impact of consultants on client/agency relationship

45. Rich Levy sees branding as a growing trend in medical advertising

46. Gil Bashe and colleagues explain how structure follows function

47. Biotech points the way to agency specialization for the biogenesis group

48. Joseph Doyle explains the West Coast difference

49. Networks can beat the conflict taboo

50. The flood vs. the ripples: an overview

Catalog

Books, media, physical & digital resources